BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $11.00 Consensus Target Price from Brokerages

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has received a consensus rating of “Hold” from the four research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $11.00.

Several equities analysts have weighed in on BTAI shares. Wall Street Zen lowered BioXcel Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a research report on Friday, July 17th.

Institutional Investors Weigh In On BioXcel Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC lifted its position in shares of BioXcel Therapeutics by 78.5% during the fourth quarter. Millennium Management LLC now owns 1,835,192 shares of the company’s stock worth $2,936,000 after acquiring an additional 807,139 shares in the last quarter. Man Group plc purchased a new position in shares of BioXcel Therapeutics in the fourth quarter valued at $91,000. State Street Corp raised its stake in shares of BioXcel Therapeutics by 19.9% during the 4th quarter. State Street Corp now owns 63,218 shares of the company’s stock valued at $101,000 after purchasing an additional 10,500 shares during the period. Jane Street Group LLC bought a new stake in shares of BioXcel Therapeutics during the 4th quarter valued at $204,000. Finally, HRT Financial LP purchased a new stake in BioXcel Therapeutics during the 4th quarter worth about $28,000. 30.68% of the stock is owned by hedge funds and other institutional investors.

BioXcel Therapeutics Stock Performance

NASDAQ:BTAI opened at $0.90 on Monday. BioXcel Therapeutics has a 52 week low of $0.74 and a 52 week high of $8.08. The firm has a 50-day moving average price of $1.05 and a two-hundred day moving average price of $1.27. The firm has a market cap of $27.84 million, a price-to-earnings ratio of -0.16 and a beta of 0.32.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.01). The business had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.38 million. As a group, sell-side analysts forecast that BioXcel Therapeutics will post -2.07 earnings per share for the current year.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.